Accounting for the Peptide & Longevity Industry — From Formation to Exit

Compounding pharmacies, telehealth clinics, longevity practices, and peptide brands all hit the same wall: generalist CPAs don’t know this industry’s entity structuring, revenue recognition, inventory, tax, or payment-processing rules. High Rock built its practice around them.

Schedule a Call

See How we Help

Where Peptide & Longevity Accounting Breaks Down

This industry combines things a generalist CPA rarely sees together: real per-protocol compounding costs, high-risk payment processing, and a regulatory environment that can reverse itself in a single quarter.

How We Help

Entity Structuring & Formation

LLC vs. S-Corp vs. C-Corp decisions for compounding pharmacies, clinics, and brands. State selection, multi-entity structures, and captive insurance setup.

ASC 606 Revenue Recognition

Matching revenue to delivery milestones for subscriptions, protocols, and telehealth plans. Deferred revenue accounting and audit-ready disclosure schedules.

Inventory & COGS Valuation

Per-protocol cost tracking, compounding waste allocation, and COGS presentation for high-SKU peptide product lines. Built for both 503A and 503B pharmacies.

Payment Processing & Reserves

Reserve accounting for high-risk merchant accounts, chargeback exposure modeling, and cash-flow forecasting when processors hold 10–30% of gross revenue.

M&A & Audit-Readiness

Financial due diligence packages, quality of earnings reports, and carve-out financials for longevity clinic acquisitions and peptide brand roll-ups.

Multi-State Sales Tax & R&D Credits

Sales-tax nexus analysis for direct-to-consumer peptide sales, plus R&D credit qualification for novel formulation and compounding protocol development.

Why High Rock

Generalist CPAs lose the thread when FDA scheduling shifts, when a 503B pharmacy restructures its revenue model, or when a telehealth clinic's payment processor freezes reserves. High Rock was built for this specific intersection — we track the regulatory calendar, know the processor risk models, and have seen the entity structures that survive acquisition due diligence.